Kumkuma (Saffron): Benefits, Evidence, Dosage & Safety

TL;DR

Kumkuma is saffron, the stigmas of Crocus sativus. A 2013 meta-analysis of 5 RCTs found large symptom reductions versus placebo and similar efficacy to antidepressants for mild-to-moderate depression: but the trials were small, short, and Iran-based. Trials used 30 mg/day for 6–8 weeks. A 2015 toxicology review advises pregnant women to avoid high doses, noting safety data are limited.

What it is

Kumkuma is saffron: the dried red stigmas of Crocus sativus L., a small purple-flowered crocus cultivated primarily in Iran, Greece, and India ("derived from the red stigmas of the Crocus flower," Tufail et al., Food Sci Nutr 2025). It is one of the costliest spices in the world (same review). Its characteristic compounds include crocin (the carotenoid behind its color), safranal (behind its aroma), and crocetin: the constituents most discussed in pharmacological and toxicological reviews (same functional review; toxicology review, PMC). Saffron's health-promoting properties are also described in ancient Chinese, Unani, and Ayurvedic prescriptions (same functional review).

Traditional use

Traditional-medicine texts have long listed saffron for low mood: as the background of a 2004 clinical trial put it, "*Crocus sativus* L. is used to treat depression. Many medicinal plants textbooks refer to this indication whereas there is no evidence-based document" (Akhondzadeh et al., BMC Complement Altern Med). In Ayurveda, kumkuma is a prized ingredient of classical preparations such as Kumkumadi Taila, and in Persian medicine saffron has centuries of use as a mood and vitality remedy. These are traditional claims, not clinical proof: the trial evidence is assessed separately below.

What modern research says

Depression

The strongest human evidence concerns mild-to-moderate depression. A 2013 meta-analysis pooled five randomized controlled trials (two placebo-controlled, three antidepressant-controlled) and found a large effect for saffron versus placebo (mean effect size 1.62, P<0.001) and a null effect versus antidepressant drugs (effect size −0.15): meaning saffron and the tested antidepressants reduced depressive symptoms to a similar degree. All five trials used 30 mg/day for 6–8 weeks, and the included trials were rated high quality (mean Jadad score 5). But the trials were small, short, and concentrated in Iran, and the authors called for larger, longer trials by research teams outside Iran before firm conclusions (Hausenblas et al., J Integr Med). Disclosure: the meta-analysis authors Drs. Anton and Hausenblas served as scientific advisors and consultants for ReBody LLC, an affiliate of Reserve Life Organics/Reserveage Organics, a marketer of a saffron-containing product. The paper states neither received personal financial gain from product sales.

A 2020 meta-analysis of 21 randomized trials found saffron significantly reduced Beck Depression Inventory scores (weighted mean difference −4.86; 95% CI −6.58 to −3.14), Beck Anxiety Inventory scores (−5.29; −8.27 to −2.31), and Pittsburgh Sleep Quality Index scores (−2.22; −2.73 to −1.72): but found no significant effect on Hamilton depression/anxiety rating scales or on C-reactive protein (Mazidi et al., Complement Ther Med). The split result (benefit on self-report scales, none on clinician-rated scales) is worth noting.

Individual trials behind these numbers include a 6-week pilot double-blind RCT (n=30) comparing saffron 30 mg/day with imipramine 100 mg/day in mild-to-moderate depression: efficacy was similar (P=0.09), with anticholinergic side effects like dry mouth and sedation seen more often in the imipramine group. The authors called it a pilot and said a large-scale placebo-controlled trial was warranted (Akhondzadeh et al., 2004). A later 6-week trial in 40 post–coronary-intervention patients found saffron 30 mg/day matched fluoxetine 40 mg/day on Hamilton depression scores (P=0.62), with similar remission, response, and adverse-event rates: but the sample was small and the period short (Akhondzadeh et al., J Affect Disord).

PMS and dysmenorrhea

A 2025 systematic review and meta-analysis of randomized trials of saffron for premenstrual syndrome and dysmenorrhea found a significant benefit for PMS symptoms (standardized mean difference −0.64; 95% CI −0.84 to −0.44) and for dysmenorrhea (−0.51; −1.01 to −0.01) (Mohammadi & Karimi, Korean J Fam Med). A second 2025 meta-analysis pooled three RCTs and likewise found a significant effect on PMS (mean difference 0.63, p=0.03), while noting methodological flaws in the included studies and calling for further trials (Maleki et al., Rev Clin Med).

What the evidence does not support (yet)

The trials are small (mostly 30–80 participants), short (typically 6–8 weeks), and concentrated in Iran. Saffron has not been shown effective for severe depression, and no trial supports using it as a replacement for prescribed antidepressants without medical supervision. Saffron has also been explored for cognitive disorders, but the human data there are preliminary (functional review).

Dosage

There is no universally established dose. In the depression trials, 30 mg/day of saffron extract was the standard regimen, studied over 6–8 weeks (Akhondzadeh et al., 2004; Hausenblas et al.). These are research doses, not personal recommendations.

Safety & contraindications

Saffron at the small doses used in trials appears well tolerated, and a toxicology review concluded that therapeutic doses in clinical trials did not produce significant toxicity: while stressing that human safety evidence is limited and inconsistent (PMC toxicology review). The commonly reported adverse effects in the depression trials were headache, nausea, anxiety, and decreased appetite (Hausenblas et al.). The cautions matter more than the reassurance:

FAQs

Does saffron help with depression?

The trial evidence is unusually favorable for an herb: a 2013 meta-analysis of 5 RCTs found a large symptom reduction versus placebo in mild-to-moderate depression (Hausenblas et al.), and a 2020 meta-analysis of 21 trials found significant improvements on depression, anxiety, and sleep self-report scales (Mazidi et al.). Trials are small, short, and mostly from Iran.

Is saffron as effective as antidepressant drugs?

In the trials so far, roughly yes: but these were small, short, Iran-concentrated pilot trials. The 2013 meta-analysis found no meaningful difference between saffron and the tested antidepressants (effect size −0.15), and individual pilot trials found saffron 30 mg/day similar to imipramine 100 mg/day and to fluoxetine 40 mg/day (Hausenblas et al.; Akhondzadeh et al., 2004). This is not a basis for switching or stopping prescribed medication without a doctor.

Does saffron help with PMS?

A 2025 meta-analysis of randomized trials found saffron significantly reduced PMS symptoms (SMD −0.64) and dysmenorrhea (SMD −0.51) (Mohammadi & Karimi). A second 2025 meta-analysis agreed but flagged methodological flaws and called for more trials (Maleki et al.).

What dose of saffron was used in studies?

Depression trials typically used 30 mg/day of saffron extract for 6–8 weeks. These are research doses, not recommendations.

Is saffron safe during pregnancy?

Medicinal amounts are not advised. A toxicology review advises pregnant women to avoid high doses because pregnancy safety data are insufficient. Higher abortion rates were reported among workers exposed to high saffron levels, but that finding cannot set a medicinal dose threshold (PMC toxicology review).

Can saffron be toxic?

At culinary and trial doses, saffron shows little toxicity, but toxic effects are dose-dependent and human safety evidence is limited and inconsistent; animal high-dose findings vary (PMC toxicology review).

Sources

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.